| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(85)90055-8 |
| P698 | PubMed publication ID | 2861454 |
| P2093 | author name string | M Colombo | |
| P M Mannucci | |||
| K Schimpf | |||
| V Carnelli | |||
| C Gazengel | |||
| G F Savidge | |||
| P2860 | cites work | Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS | Q28262859 |
| Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients | Q34259595 | ||
| Plasma derivatives and viral hepatitis | Q40266065 | ||
| Absence of antibodies to AIDS virus in haemophiliacs treated with heat-treated Factor VIII concentrate | Q43586042 | ||
| Evidence for existence of at least two types of factor-VIII-associated non-B transfusion hepatitis | Q44394188 | ||
| Isolation of new lymphotropic retrovirus from two siblings with haemophilia B, one with AIDS | Q44866062 | ||
| Use of and interpretation of results using inocula of hepatitis B virus with known infectivity titers | Q45794085 | ||
| Interference between non-A, non-B and hepatitis B virus infection in chimpanzees | Q45795851 | ||
| Transmission of serum parvovirus-like virus by clotting-factor concentrates | Q45806240 | ||
| Inactivation of lymphadenopathy-associated virus by heat, gamma rays, and ultraviolet light | Q45840287 | ||
| Hemophilia, hepatitis, and the acquired immunodeficiency syndrome | Q45861937 | ||
| Reduction in risk of hepatitis transmission by heat-treatment of a human Factor VIII concentrate. | Q52849976 | ||
| Non-A, maybe-B hepatitis. | Q52849980 | ||
| Detection of reverse transcriptase activity in association with the non-A, non-B hepatitis agent(s) | Q72748701 | ||
| P433 | issue | 8445 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1-4 | |
| P577 | publication date | 1985-07-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate | |
| P478 | volume | 2 |
| Q42978122 | A high prevalence of antibodies to hepatitis C virus among commercial plasma donors from Western India |
| Q45054230 | A prospective study of cryoprecipitate administration: absence of evidence of virus infection |
| Q45869176 | AIDS, hepatitis and hemophilia in the 1980s: memoirs from an insider |
| Q34422609 | Advances in the treatment of von Willebrand disease |
| Q33634035 | Anti HBs protection in hospital workers vaccinated against hepatitis B: policy implications of a pilot study |
| Q37203717 | Anti-HTLV-III positive laboratory reagents |
| Q42987959 | Antibodies against hepatitis C in a population of Swedish haemophiliacs and heterosexual partners |
| Q34070790 | Apnoeic episodes induced by smothering: two cases identified by covert video surveillance |
| Q38602709 | Blood transfusion and hepatitis: still a threat? |
| Q43189415 | Cholesterol emboli may mimic systemic vasculitis |
| Q35604929 | Clinical significance of IgG subclass deficiency |
| Q37107753 | Demonstration of HIV-1 infected cells in human placenta by in situ hybridisation and immunostaining |
| Q34072260 | Effect of fear of AIDS on sharing of injection equipment among drug abusers |
| Q42977231 | Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs |
| Q38390368 | Electrolytes and glucose in cerebrospinal fluid of premature infants with intraventricular haemorrhage: role of potassium in cerebral infarction |
| Q33732203 | Electrophysiological assessment of central and peripheral motor routes to the lingual muscles |
| Q57083497 | Enhanced microfiltration of γ-globulin solution upon treatment of NaCl addition and/or DNase digestion |
| Q34210001 | Evidence for persistent hepatitis C virus (HCV) infection in hemophiliacs |
| Q36850562 | Excitability of the motor cortex to magnetic stimulation in patients with cerebellar lesions |
| Q34070520 | Exertional gastro-oesophageal reflux: a mechanism for symptoms in patients with angina pectoris and normal coronary angiograms |
| Q36138249 | Factor IX concentrates: the new products and their properties |
| Q34731218 | Factor VIII concentrate for hemophilia: comparison of two heat-treated products. |
| Q37882787 | Factor VIII safety: plasma-derived versus recombinant products |
| Q40761966 | HIV transmission to patients with hemophilia by heat-treated, donor-screened factor concentrate |
| Q37810630 | HIV-1 infection in haemophilia |
| Q45886493 | Heat-treated NHS factor VIII concentrate in the United Kingdom--a preliminary study |
| Q34048559 | Hemophilia: an amazing 35-year journey from the depths of HIV to the threshold of cure |
| Q45828476 | Hepatitis B virus, hepatitis non-A, non-B virus and hepatitis delta virus in lyophilized antihemophilic factor: relative sensitivity to heat |
| Q45881803 | Hepatitis C antibody and chronic liver disease in haemophilia |
| Q38841718 | Hepatitis C seropositivity in HIV-negative children with severe haemophilia |
| Q42985704 | Hepatitis C virus seroprevalence in Italian haemophiliacs injected with virus-inactivated concentrates: Five year follow-up and correlation with antibodies to other viruses |
| Q39511102 | Human retroviruses and paediatric disease |
| Q42722102 | Hypocholesterolaemia in hairy cell leukemia |
| Q42562758 | Improving the poor prognosis of oral squamous cell carcinoma |
| Q42980369 | Intravenous immunoglobulin and hepatitis C virus: the Scandinavian experience |
| Q35066445 | Ischaemic brain lesions diagnosed at birth in preterm infants: clinical events and developmental outcome |
| Q39612039 | Keratin profiles of normal and malignant oral mucosa using exfoliative cytology |
| Q68858286 | Maternal and fetal screening |
| Q24645561 | Mechanisms behind hypocholesterolaemia in hairy cell leukaemia |
| Q69872030 | Non-A, non-B hepatitis after factor VIII concentrate treated by heating and chloroform |
| Q38138549 | Noncardiac complications of open-heart surgery |
| Q33931169 | Outpatient treatment of perianal warts by scissor excision |
| Q93866052 | Patient-to-patient transmission of hepatitis C virus |
| Q37891089 | Pharmacotherapy of haemophilia A. |
| Q38366499 | Plasma hypoxanthine: a marker for hypoxic-ischaemic induced periventricular leucomalacia? |
| Q43749890 | Practical approach to the discovery of a positive HCV serology in a blood donor |
| Q42865895 | Practising public health in primary care is easier said than done |
| Q42997576 | Prevalence of hepatitis C virus infection and HCV genotypes among hemophiliacs in the State of Bahia, Northeastern Brazil: analysis of serological and virological parameters |
| Q45887599 | Prospective study of hepatitis after factor VIII concentrate exposed to hot vapour |
| Q43824268 | Protein modification during anti-viral heat-treatment bioprocessing of factor VIII concentrates, factor IX concentrates, and model proteins in the presence of sucrose. |
| Q73258785 | Protein modification during antiviral heat bioprocessing |
| Q39491652 | Rationale for surrogate testing to detect non-A, non-B hepatitis |
| Q37823473 | Recent advances in the preparation of plasma-derived and recombinant coagulation factor VIII. |
| Q41902204 | Reduced risk of non-A, non-B hepatitis after a first exposure to 'wet heated' factor VIII concentrate |
| Q45876072 | Risk factors for infection with HBV and HCV in a largecohort of hemophiliac males |
| Q35354493 | Safety aspects in the manufacturing of plasma-derived coagulation factor concentrates |
| Q35626058 | Safety trial of heated factor VIII concentrate (8Y). |
| Q43165882 | Second malignant tumours in head and neck cancer |
| Q39592379 | Small-pool high-yield factor VIII production |
| Q41107853 | The choice of plasma-derived clotting factor concentrates |
| Q39662715 | The development of virus-free labile blood derivatives--a review |
| Q35252058 | The impact of clotting factor concentrates on the immune system in individuals with hemophilia |
| Q33734815 | The silent period induced by transcranial magnetic stimulation in muscles supplied by cranial nerves: normal data and changes in patients |
| Q69739062 | The use of blood components in the treatment of congenital coagulation disorders |
| Q39597711 | The viral safety of intravenous immunoglobulin |
| Q39491627 | Transfusion associated AIDS. |
| Q39491700 | Transfusion-associated hepatitis B: past and present |
| Q33839310 | Vegetarian diet and cobalamin deficiency: their association with tuberculosis |
| Q40751006 | Viral safety issues: plasma-derived factor VIII. |
| Q45887091 | Viral safety of plasma-derived and recombinant products used in the management of haemophilia A and B. |
| Q43877706 | Virucidal treatment of clotting factor concentrates |
| Q69869220 | Wet heating for safer factor VIII concentrate? |
Search more.